Compare JD.Com Inc (JD) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs Natera Inc. Common Stock — how do they compare? JD.Com Inc trades at $26.65 (market cap $36.51B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and JD.Com Inc pays a 3.73% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold JD.Com Inc for 86 Days and Natera Inc. Common Stock for 0 Days on average.
| JD | NTRA | |
|---|---|---|
Market Cap | $36.51B | $57.03B |
Volume | 8,583,924 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.53 | $425.64 |
52-Week Low | $25.19 | $179.42 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $19.13B | $56.18B |
Dividend Yield | 3.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $26.68, down 0.15% on the day, with a bearish technical signal driven by moving averages. The stock shows strong analyst support with a consensus price target of $35.38 and a 69.57% buy rating. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.93 surpassing the $0.86 estimate. Revenue for 2025 reached $1.31 trillion, though net income margin declined to 1.49% from 3.56% in 2024. The company is pursuing growth via acquisitions, such as the pending $2.5 billion Ceconomy deal, pending EU approval.
JD.com presents a value opportunity with low valuation multiples (P/E of 17.78, P/S of 0.2) and a robust balance sheet featuring $234 billion in cash. However, risks include regulatory scrutiny from EU probes, competitive pressures in Chinese e-commerce, and margin compression. The stock's upside is supported by strong free cash flow and institutional accumulation, but investors must weigh geopolitical and execution risks against the discounted valuation.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
